What changed
$AZN — HOLD 📊 | 6 MONTHS THESIS
🎯 latest | Rev $2.7B | EPS $1.29 vs $1.27 🟢
💡 Consensus expected a steady quarter with no major surprises. The actual beat was marginal (1.4% above estimate), and management likely maintained full-year guidance without raising it. Markets anticipated a larger beat given recent peer performance, so the in-line result fails to excite.
📉 Reward/risk: 1.03:1
🏢 Business Quality: 8/10 - AZN has a strong oncology pipeline, broad portfolio, and consistent execution, but it is a mature pharma facing patent cliffs and pricing pressure.
📊 Valuation: rich - relative to large-cap pharma peers (P/E 15-20x) and its own 5-year historical average (22-25x forward), AZN's 34x P/E on TTM EPS of ~$5.20 is...
📊 Our read: HOLD. Full analysis →
https://stockduty.xyz/s/AZN0616